[CLSTR]
< Back to situation

[REVISION HISTORY]

Eli Lilly retatrutide development and black market issues

Updated 5 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-23 11:57 UTC → 2026-09-05 02:16 UTC · added removed

Eli Lilly retatrutide development and legal actions black market issues

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks, with notable improvements weeks in blood-sugar control for those with type-2 diabetes. While the drug acts on three hormonal pathways—GLP-1, GIP, and glucagon—common side effects included nausea and diarrhea, and a small subgroup showed a higher incidence of serious cardiovascular events. Further details from late-stage clinical trials indicate that the drug’s triple-agonist approach may influence how the body utilizes energy rather than just suppressing appetite. In an 80-week study involving individuals with severe obesity and existing cardiovascular disease, participants receiving the highest dose lost an average of 22.6% of their body weight. In while a separate study involving individuals with obesity but without diabetes, the diabetes saw average weight loss reached reach 28.3% at the highest dose. The drug’s triple-agonist approach—targeting GLP-1, GIP, and glucagon—may influence how the body utilizes energy rather than just suppressing appetite. Common side effects include nausea and diarrhea, and a small subgroup showed a higher incidence of serious cardiovascular events. Eli Lilly plans to seek FDA approval in the United States during the first quarter of 2027. To provide access to the experimental drug, access, Lilly launched a compassionate-use program in the United States. This program is restricted to U.S. for adults with refractory obesity and at least two serious weight-related complications who are ineligible for ongoing clinical trials. Lilly warned that products sold outside of regulated trials may contain incorrect doses or unknown ingredients. Concurrently, As the drug remains in the clinical trial phase without regulatory approval, counterfeit versions are flooding black markets. In the UK, illicit vials are reportedly being distributed through gyms, beauty salons, hairdressers, social media, and street vendors. Health professionals have expressed concern regarding individuals injecting these unregulated, illegal substances. Consequently, Eli Lilly has initiated legal action against various U.S. entities, including compounding pharmacies, pharmacies and medical spas, and online sellers, for the illegal sale of black-market retatrutide. The company has referred over 200 entities to the FDA and the Department of Justice, flagging more than 14,000 illegal advertisements and product listings globally. The FDA has maintained that the sale of unapproved retatrutide to consumers is illegal and cannot be lawfully compounded.

Versions

  1. 2026-09-05 02:16 UTC Eli Lilly retatrutide development and black market issues
  2. 2026-08-23 11:57 UTC Eli Lilly retatrutide development and legal actions
  3. 2026-08-18 11:34 UTC Eli Lilly retatrutide development and legal actions
  4. 2026-08-15 01:02 UTC Eli Lilly retatrutide development and legal actions
  5. 2026-08-12 10:45 UTC Eli Lilly retatrutide development and legal actions
  6. 2026-08-05 23:12 UTC Eli Lilly Retatrutide obesity drug development

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.